Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitorbased regimens in Asian HIV-infected children

Antiviral Therapy

Volumn 18, Issue 4, 2013, Pages 591-598

  Bunupuradah, Torsak ^a   Puthanakit, Thanyawee ^a,b   Fahey, Paul ^c   Kariminia, Azar ^c   Yusoff, Nik K N ^d   Khanh, Truong H ^e   Sohn, Annette H ^f   Chokephaibulkit, Kulkanya ^g   Lumbiganon, Pagakrong ^h   Hansudewechakul, Rawiwan ⁱ   Razali, Kamarul ^j   Kurniati, Nia ^k   Huy, Bui V ^l   Sudjaritruk, Tavitiya ^m   Kumarasamy, Nagalingeswaran ⁿ   Fong, Siew M ^o   Saphonn, Vonthanak ^p   Ananworanich, Jintanat ^a,b,q  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Hospital Raja Perempuan Zainab II   (Malaysia)

^e Children Hospital Number 1   (Viet Nam)

^f Foundation for AIDS Research   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h KHON KAEN UNIVERSITY   (Thailand)

ⁱ CHIANGRAI PRACHANUKROH HOSPITAL   (Thailand)

^j HOSPITAL KUALA LUMPUR   (Malaysia)

^k CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^l NATIONAL HOSPITAL OF PEDIATRICS   (Viet Nam)

^m CHIANG MAI UNIVERSITY   (Thailand)

ⁿ YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^o Hospital Likas   (Malaysia)

^p National Pediatric Hospital   (Cambodia)

^q THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS DIDANOSINE; ATAZANAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE PLUS LAMIVUDINE; DIDANOSINE PLUS STAVUDINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SYNDROME DELINEATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA, SOUTHEASTERN; BLOOD GLUCOSE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPOPROTEINS; LOPINAVIR; MALE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 84885343575     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2494     Document Type: Article

References (35)

1. World Health Organization. Antiretroviral Therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach-2010 revision. Geneva: World Health Organization 2010.
2. World Health Organization. Antiretroviral Therapy of HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision. Geneva: World Health Organization 2010.
3. Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai 2008; 91:1925-1935.
4. Rudin C, Wolbers M, Nadal D, Rickenbach M, Bucher HC. Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. Arch Dis Child 2010; 95:478-481.
5. Delaugerre C, Teglas JP, Treluyer JM, et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2004; 37:1269-1275.
6. Bunupuradah T, Aurpibul L, Ananworanich J, Puthanakit T. The effectiveness of highly active antiretroviral therapy among HIV-infected children in Asian countries. Asian Biomedicine 2009; 3:89-100.
7. Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008; 22:1305-1312.
8. Puthanakit T, Jourdain G, Suntarattiwong P, et al. High virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited setting. AIDS Res Ther 2012; 9:20.
9. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452.
10. Rhoads MP, Lanigan J, Smith CJ, Lyall EG. Effect of specific antiretroviral therapy (ART) drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr 2011; 57:404-412.
11. Kariminia A, Chokephaibulkit K, Pang J, et al. Cohort profile: The TREAT Asia Pediatric HIV Observational Database. Int J Epidemiol 2011; 40:15-24.
12. Puthanakit T, Kerr S, Ananworanich J, Bunupuradah T, Boonrak P, Sirisanthana V. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J 2009; 28:488-492.
13. Larrú B, Resino S, Bellon JM, et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. J Antimicrob Chemother 2008; 61:183-190.
14. World Health Organization. WHO growth chart 2006. (Accessed 11 June 2013.) Available from http://www.who. int/growthref/en/
15. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11 2002; 246:1-190.
16. Hansudewechakul R, Sirisanthana V, Kurniati N, et al. Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database. J Acquir Immune Defic Syndr 2010; 55:503-509.
17. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIVinfected children and youth. AIDS 2009; 23:661-672.
18. Botton J, Heude B, Kettaneh A, et al. Cardiovascular risk factor levels and their relationships with overweight and fat distribution in children: the Fleurbaix Laventie Ville Sante II study. Metabolism 2007; 56:614-622.
19. National Cholesterol Education Program (NCEP). Highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89:495-501.
20. The American Heart Association. What your cholesterol levels mean. (Updated 12 October 2012. Accessed 11 June 2013.) Available from http://www.heart.org/HEARTORG/Conditions/AboutCholesterol/What-Your-Cholesterol- Levels-Mean-UCM-305562-Article.jsp
21. Bittner V, Johnson BD, Zineh I, et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 2009; 157:548-555.
22. TApHOD, IeDEA Southern Africa Paediatric Group. A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. J Int AIDS Soc 2011; 14:7.
23. Scherrer AU, von Wyl V, Boni J, et al. Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2011; 57:24-31.
24. Puthanakit T, van der Lugt J, Bunupuradah T, et al. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob Chemother 2009; 64:1080-1086.
25. The PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised Phase 2/3 trial. Lancet Infect Dis 2011; 11:273-283.
26. Bunupuradah T, Suntarattiwong P, Li A, et al. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. Int J Infect Dis 2010; 14:e311-e316.
27. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-291.
28. Duval X, Journot V, Leport C, et al. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis 2004; 39:248-255.
29. Bunupuradah T, van der Lugt J, Kosalaraksa P, et al. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther 2009; 14:241-248.
30. Quijada Z, Paoli M, Zerpa Y, et al. The triglyceride/HDLcholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. Pediatr Diabetes 2008; 9:464-471.
31. Tebas P, Henry WK, Matining R, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS ONE 2008; 3:e2021.
32. Machado DM, Gouvea Ade F, Cardoso MR, et al. Factors associated with clinical, immunological and virological responses in protease-inhibitor- experienced Brazilian children receiving highly active antiretroviral therapy containing lopinavir-ritonavir. Braz J Infect Dis 2007; 11:16-19.
33. Pujades-Rodríguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 2010; 304:303-312.
34. Dollfus C, Le Chenadec J, Faye A, et al. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). Clin Infect Dis 2010; 51:214-224.
35. The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011; 377:1580-1587.